Analyst Price Targets — COR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 20, 2026 11:47 am | David Toung | Argus Research | $380.00 | $340.00 | StreetInsider | Cencora Inc (COR) PT Raised to $380 at Argus |
| October 16, 2026 11:52 am | — | UBS | $400.00 | $341.41 | TheFly | Cencora price target lowered to $400 from $430 at UBS |
| August 19, 2026 7:07 am | Ryan Halsted | RBC Capital | $330.00 | $316.13 | StreetInsider | RBC Capital Starts Cencora Inc (COR) at Sector Perform |
| August 7, 2026 1:28 pm | — | Morgan Stanley | $346.00 | $323.29 | TheFly | Cencora price target raised to $346 from $342 at Morgan Stanley |
| August 6, 2026 1:18 pm | — | Robert W. Baird | $370.00 | $313.37 | TheFly | Cencora price target raised to $370 from $340 at Baird |
| August 6, 2026 12:35 pm | Kevin Caliendo | UBS | $430.00 | $313.51 | TheFly | Cencora price target raised to $430 from $412 at UBS |
| August 6, 2026 11:49 am | — | Evercore ISI | $350.00 | $317.22 | TheFly | Cencora price target raised to $350 from $330 at Evercore ISI |
| June 10, 2026 9:12 am | — | Barclays | $350.00 | $279.57 | TheFly | Cencora price target lowered to $350 from $425 at Barclays |
| May 11, 2026 10:23 am | Stephen Baxter | Wells Fargo | $331.00 | $261.08 | TheFly | Cencora price target lowered to $331 from $429 at Wells Fargo |
| May 8, 2026 1:12 pm | — | Morgan Stanley | $342.00 | $265.58 | TheFly | Cencora price target lowered to $342 from $400 at Morgan Stanley |
Latest News for COR
IFP Advisors Inc raised its holdings in Cencora, Inc. (NYSE: COR) by 227.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,264 shares of the company's stock after acquiring an additional 14,078 shares during the quarter. IFP Advisors Inc's holdings
Frank Rimerman Advisors LLC grew its holdings in Cencora, Inc. (NYSE: COR) by 235.3% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 4,336 shares of the company's stock after buying an additional 3,043 shares during the quarter. Frank Rimerman
Cencora (NYSE: COR - Get Free Report) and Option Care Health (NASDAQ: OPCH - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings. Earnings and Valuation This table compares Cencora and
Cencora (COR) stands to benefit from AI-driven increases in prescription volumes as regulatory pilots expand automated prescribing. COR's operational leverage and AI-enabled efficiency improvements have driven adjusted operating income up 17% YoY, outpacing 4.9% sales growth. Trading at a forward GAAP P/E of 17.7x—about 25% below sector median—COR merits a 12.5% re-rating, targeting $365–$366 per share.
NorthCrest Asset Manangement LLC increased its holdings in Cencora, Inc. (NYSE: COR) by 1,255.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 25,286 shares of the company's stock after buying an additional 23,420 shares during the quarter. NorthCrest Asset
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.